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Using arbitrary primed-PCR (AP-PCR), we have identified a novel genetic alteration located at chromosome 11q23.2 and this genetic
alteration was common in 38% of the human Wilms tumour samples analysed. Further characterisation by cloning and sequencing of
this genomic region revealed that it represents a part of an uncharacterised gene. We have named this gene as Sporadic Kidney
Cancer Gene-1 (SKCG-1). Using fluorescence in situ hybridisation (FISH) approach, we established its localisation on the chromosome
11q23.2. Northern analysis revealed the transcript size of SKCG-1 of 2.09kb and this was further confirmed by full-length cDNA
sequence. Sequence analysis revealed an active translation start site (ATG sequence), a polyadenylation signal sequence (AATAAA),
and an open reading frame (ORF) encoding a peptide of 124 amino acids in the cDNA sequence of SKCG-1. Analysis of genomic
sequence of SKCG-1 revealed a promoter region containing TATA box located at  13bp upstream of transcription start site. The
AP-PCR, SCAR, and Southern blot analyses indicated genomic loss of SKCG-1 in Wilms tumours. The transcript of SKCG-1 was
abundantly present in brain, kidney, liver, testis, salivary gland, foetal brain, foetal liver, whereas relatively lower expression in heart,
stomach, prostate and no expression in spleen, colon, lung, small intestine, muscle, adrenal gland, uterus, skin, PBL, and bone marrow
was detected. The expression of this gene transcript was either very less or undetectable in Wilms and breast tumours compared to
their matched uninvolved tissues. Inhibition of SKCG-1 by siRNA resulted in increased cell proliferation of kidney epithelial cells. Based
on the presence of two transmembrane regions in its peptide, SKCG-1 has been predicted as a transmembrane protein. Thus, the
findings of this study revealed (i) SKCG-1, a new gene located at 11q23.2 and harbouring genetic alteration in Wilms tumours, (ii) the
presence of SKCG-1 gene transcripts in various human normal tissues and its lower expression or absence in Wilms and breast
tumours indicate that it may be associated with tumour growth suppressor activity, (iii) the presence of an open reading frame in the
cDNA sequence of SKCG-1 indicates that it has potential to encode a protein, (iv) increased cell growth by silencing this gene in
HEK293 cells further supports a potential role of this gene in growth of kidney epithelial cells. Our findings suggest that SKCG-1 may
have a tumour suppressor role, and implicate genetic alteration in this gene as a potential oncogenic pathway and therapeutic target
in kidney and breast cancer.
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Altered expression of those genes that control cell proliferation
and differentiation is a common end result of genetic alterations
that occur in human tumours and is a crucial step in tumori-
genesis. Identification and characterisation of all possible genetic
alterations that predispose to cancer are of utmost importance to
understand the development of cancer. In this study, by using
arbitrary primed-PCR (AP-PCR) assay, we identified a new gene,
SKCG-1, harbouring genetic alteration in 38% of the human
sporadic Wilms tumour samples analysed. Wilms tumour or
Nephroblastoma is an embryonal malignancy of the kidney,
affecting about 1 in 10000 children (Matsunaga, 1981). It
comprises about 6% of all childhood cancers and is a major
paediatric cancer burden at the global level (Volkher et al, 2001).
The important discoveries made in the past several years regarding
molecular events underlying Wilms tumorigenesis have indicated
the involvement of two tumour suppressor genes namely WT1 and
WT2 located at 11p13 and 11p15, respectively (Mannens et al,
1988; Koufos et al, 1989; Call et al, 1990; Gessler et al, 1990).
Besides these two genes, many other mutational events, such as
allelic loss of chromosome 16q (Maw et al, 1992), loss of
heterozygosity at 11q23.3-q-ter region (Radice et al, 1995), and
high rate of P53 mutations located at 17p13 (Bardeesy et al, 1994)
in Wilms tumour indicate the involvement of these genes/loci with
Wilms tumour formation. Association of a particular genetic
abnormality with specific histopathology of Wilms tumour
indicates that WT development involves several, probably alter-
native, genetic pathways, but there is still an incomplete picture as
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they are controlled (Grundy et al, 1994; Hing et al, 2001). Thus, a
complete description of molecular defects in individual WTs is
highly warranted.
Using AP-PCR method, we have recently identified a novel
mutation located at 17q11.2 in 80% of the sporadic breast tumour
samples analysed (Singh and Roy, 2001). Here we report the
identification and characterisation of a new gene, SKCG-1, which is
altered in human Wilms and breast tumours. We have cloned the
full-length cDNA sequence of SKCG-1, established its chromo-
somal localisation, determined its structural analysis and coding
potential, analysed its expression in various normal human tissues,
including Wilms and breast tumours and their corresponding
uninvolved tissues, and tested its function in cell growth by
silencing it.
MATERIALS AND METHODS
Chemicals
The AmpliTaq DNA polymerase (Stoffel fragment), dNTPs and
mineral oil were purchased from PE Applied Biosystems (Foster
City, CA, USA). A set of 20 OPA series oligonucleotide random
ten-mer primers was purchased from Operon technologies
(Alameda, CA, USA). The DIG high prime DNA labelling and
detection kit was obtained from Roche Diagnostics (Indianapolis,
IN, USA).
DNA and RNA extraction
Thirteen human Wilms tumour tissues (six Caucasian American
cases, six African-American cases, and one Asian), out of which 10
with matching tumour-normal pair and three tumours without
matching normal as well as seven breast tumours with matching
normal tissues were obtained through NCI Tissue Procurement
Facility, Comprehensive Cancer Center (University of Alabama at
Birmingham, USA). Human embryonic kidney epithelial cell line,
HEK-293, was obtained from ATCC and propagated in DMEM/F12
growth medium with 10% FBS. Genomic DNAs were isolated from
tumour and corresponding normal frozen tissues following the
methods as described previously by us (Singh and Roy, 1999).
Total RNA was isolated from the kidney and breast tumours, their
corresponding uninvolved tissues, as well as from in vitro grown
embryonic kidney epithelial cells (HEK-293) following the Trizol
method (Invitrogen, Carlsbad, CA, USA). The DNA and RNA were
quantified spectrophotometrically, and purity as well as integrity
was checked by ethidium bromide staining after resolving on 1.5%
agarose gel (for DNA) and on 1% agarose gel in 1  formaldehyde
buffer (for RNA).
AP-PCR
AP-PCR was performed following the method as described
previously by us (Singh and Roy, 2001). Amplifications were
carried out in 25ml of reaction mixture containing 100mM each of
dATP, dCTP, dGTP, dTTP; 2.5mM MgCl2; 2.5mlo f1 0   enzyme
assay buffer, 1.5 unit of Taq DNA polymerase (stoffel) and 75ng of
genomic DNA. From a total of 15 primers used, the OPA14
(50-TCTGTGCTGG-30) was the only primer that revealed genetic
alteration in the AP-PCR profile of Wilms tumour DNA. DNA
amplification was performed in a Perkin-Elmer Cetus DNA
thermal cycler programmed for 45 cycles: first cycle (3.5min at
921C, 1min at 341C, 2min at 721C), next 44 cycles (1min at 921C,
1min at 341C, 2min at 721C), followed by a final extension cycle of
15min at 721C. AP-PCR products were separated by electro-
phoresis in denaturing (4.0% acrylamide and 50% urea) sequencing
gel and visualised by silver staining method (Singh and Roy, 1999).
Each experiment was repeated three to four times.
Cloning and sequencing of AP-PCR amplified product
AP-PCR product of 475bp amplified by OPA14 (50-
TCTGTGCTGG-30) primer was cloned and sequenced for further
characterisation. This band in the AP-PCR fingerprint of un-
involved kidney DNA was excised from the gel, and DNA was
eluted. The eluted DNA was reamplified with the same AP-PCR
primer as before and using the same concentrations of reaction
mixture constituents and PCR cycle conditions as described above.
The PCR product was analysed on agarose gel to confirm its size
and purity. The reamplified 475bp DNA was cloned using TA
cloning kit (Invitrogen, Carlsbad, CA, USA). The presence of an
appropriate insert size was determined by restriction analysis of
recombinant plasmid DNA, and it was further confirmed by
hybridising it with pure 475bp AP-PCR amplified DNA as a probe.
The insert was sequenced with automated DNA sequencer through
DNA sequencing Core Facility, Comprehensive Cancer Center,
UAB. Sequences obtained from several clones were compared with
known sequences in the GenBank database using the BLASTn and
BLASTx program.
Southern blot analysis
Total DNA was digested individually with restriction enzymes
(BamH1, Sma1) according to the manufacturer’s instructions and
fractioned by 0.85% agarose gel electrophoresis (AGE) in TAE
buffer (Maniatis et al, 1982). The separated DNA was transferred to
nylon membrane (Hybond N
þ, Amersham Pharmacia Biotech
Ltd.) by Southern blotting. The membrane was probed with
[a-
32P]-dCTP random primed-labelled 475bp AP-PCR amplified
fragment (cloned) as SKCG-1 probe and the signals were detected
by autoradiography of X-ray films. The same membrane was
stripped off the SKCG-1 probe and then rehybridised with GAPDH
probe.
Northern blot analysis
Total RNA (5, 10, 20mg) isolated from HEK 293 cells was
fractionated by electrophoresis in 1.0% agarose gel containing
formaldehyde and transferred to Hybond-N
þ (Amersham) by
capillary blotting. Membranes were hybridised with non-radio-
active PCR-generated-DIG-labelled SKCG-1 or GAPDH (glycer-
aldehydes-3-phosphate dehydrogenase) gene-specific probes and
washed according to protocols provided by the manufacturer of
DIG high prime DNA labelling and detection kit (Roche).
Isolation and sequencing of full-length SKCG-1 cDNA
The full-length SKCG-1 cDNA sequence was obtained by EST
sequencing and Rapid Amplification of cDNA ends (RACE)
method as described previously (Frohman, 1993). A 1.37kb
sequence of SKCG-1 gene was obtained by sequencing of an EST
clone (GenBank accession number AA935177) showing 100%
similarity with 475bp sequence. The remaining (0.720kb)
sequence was obtained by 50 and 30RACE. 50 and 30 RACE-PCRs
were carried out with total RNA obtained from normal human
kidney and using the GeneRacer kit (Invitrogen). PCR reactions
were carried out as specified by the manufacturer of GeneRacer kit
(Invitrogen). To obtain 50-ends, initial PCR was performed with
gene-specific primer (50-GCTGCGCTGTGGGTATGTAAGATGTT-
30) followed by a nested PCR with nested primer (50-GGATACA
CAGGGACTGCTTTG-30) to increase the gene specificity of PCR
product. Similarly, 30-ends sequence was obtained by 30RACE
using gene-specific primer (50-GGAGGCACCACTTGGTAACA-30)
and nested PCR with primers (50-CCTGAGTGTCTCTGCCGTGT-
30). These GSPs were designed based on sequence data obtained
from 1.37kb EST sequence. Final full-length cDNA sequence of
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assigned accession number is AY662656.
Bioinformatic analysis of SKCG-1
The sequence homology search and ORF analysis was performed
by using software available at NCBI Website (www.ncbi.nlm.nih.
gov). The prediction of potential methylation sites (CpG sites) in
the promoter region sequence of SKCG-1 was analysed by
computer-based free software (www.ebi.ac.uk/servicestmp). The
type of protein (soluble or membrane) and its cellular localisation
was predicted by using SOSUI software system (http://sosui.
proteome.bio.tuat.ac.jp). The detail structure of SKCG-1 peptide,
location of transmembrane region in the peptide, its hydropathy
profile and helical wheel diagram is available at the EMBL
bioinformatic harvester website (http://harvester.embl.de/harvester/
Q51SC8).
Reverse transcriptase-polymerase chain reaction
(RT–PCR)
The transcript level of SKCG-1 was measured by semiquantitative
PCR. Oligo dT-primed first strand cDNA was synthesised from
DnaseI-treated total RNA (2mg) using Superscript II reverse
transcriptase (Invitrogen). The PCR amplification was performed
in a Perkin-Elmer Cetus DNA thermal cycler programmed for first
cycle of 941C for 3min, followed by 35 cycles 1min of denaturation
at 941C, 1min of annealing at 591C, 1min of extension at 721C. The
PCR was completed by a final extension cycle at 721C for 10min.
PCR reactions with GAPDH-specific primers were also performed
as control. SKCG-1 gene-specific PCR fragment of 300bp was
amplified by forward (50-GATAGGGAAGCCAAAGACAC-30) and
reverse (50-CCAGAGCAGGAGGATAATAAA-30) primers. Simi-
larly, a 367bp fragment of housekeeping gene, GAPDH was
amplified by forward (50-GTCGCTGTTGAAGTCAGAGGA-30) and
reverse (50-TTCATGACAACTTTGGTATCG-30) primers. Samples
were analysed by electrophoresis on 1.5% agarose gels.
Tissue distribution of SKCG-1 gene expression
The expression of SKCG-1 gene among the various tissues was
analysed by PCR using tissue-specific cDNA panel (OriGene
Technologies). The primers and the PCR conditions were the same
as mentioned in the RT–PCR protocol. Reactions with b-actin-
specific primers were used as a control according to the
manufacturer’s instructions.
Chromosomal localisation of the SKCG-1 gene by
fluorescence in situ hybridisation
Chromosomal localisation of SKCG-1 gene was performed by FISH
following the method of Stokke et al (1995). Human BAC clone
genomic library was screened using original 475bp AP-PCR
fragments as probe. Sequencing of the positive BAC clones using
the primer designed from 475bp region revealed a clone with
entire 475bp sequences. Plasmid DNA was purified from this clone
and was labelled with digoxigenin dUTP by nick translation.
Labelled probe was combined with sheared human DNA and
hybridised to normal metaphase chromosomes derived from
phytohaemagglutinin-stimulated peripheral blood lymphocytes in
a solution containing 50% formamide, 10% dextran sulfate and
2 SSC. Specific hybridisation signal were detected by incubating
the hybridised slides in fluoresceinated anti-digoxigenin anti-
bodies followed by counter staining with 4-6-diamidino-
2-phenylindole (DAPI) for one-colour experiments. Probe detection
for two-colour experiments was accomplished by incubating the
slides in fluoresceinated antidigoxigenin antibodies and Texas red
followed by counterstaining with DAPI. Ideograms and estimates
of distance of SKCG-1 gene locus from the centromere were
calculated following the method as described by Francke (1994).
SKCG-1 gene transcript silencing by siRNA
Silencing of SKCG-1 was achieved by using the Dicer siRNA
generation kit (Gene Therapy Systems, Inc., CA, USA) and
following the manufacturer instructions. Briefly, double-stranded
RNA (dsRNA) template was generated by T7 RNA polymerase-
mediated in vitro transcription from 500bp double-stranded target
genomic region of SKCG-1. Double-stranded RNA was digested
with the recombinant dicer enzyme to generate 22bp siRNA.
Overnight grown 50–70% confluent adherent HEK293 cells were
transfected with siRNA following the Lipofectamine method. To
determine the extent of gene silencing, total RNA was isolated from
siRNA transfected and untransfected (as control) HEK293 cells
after 48h of post-transfection. RT–PCR was performed using the
total RNA and transcript level of SKCG-1 was determined following
the method as described above in RT–PCR section. Cell growth
was measured by counting the cells before isolating the RNA from
these cells.
RESULTS
Identification of mutation in human Wilms tumour
samples
To screen the mutations at genome-wide level, we compared the
genomic fingerprint patterns of human Wilms tumours vs matched
nonmalignant (uninvolved) tissues by AP-PCR analysis. Out of 15
different random primers used, one primer (OPA14) revealed
multifold decreased intensity of 475bp AP-PCR amplified DNA
fragment in 38% (5 of 13) of the tumour samples as compared to
uninvolved kidney tissues from the same individuals (Figure 1).
Out of these five patients, one was male (5 years old Caucasian-
American male, Figure 1, lane 5) and the remaining four were
female (10 months old African-American female, Figure 1, lane 7; 5
years old Caucasian-American female, Figure 1, lane 9; 2 years old
African-American female, Figure 1, lane 11; 4 years old Caucasian-
American female, Figure 1, lane 22).
400 bp
600 bp
800 bp
T13T12T11T10N10T9N9T8N8T7N7T6N6T5N5T4N4T3N3T2N2T1N1 M
23 21 19 17 15 13 11 9 7 5 3 1
24 22 20 18 16 14 12 10 8 6 4 2
Figure 1 Representative AP–PCR fingerprints generated by primer
OPA14 (50-TCTGTGCTGG-30) from Wilms tumours (T1–T13) and
corresponding uninvolved normal (N1–N13) kidney tissue DNA. Arrow
indicates the 475bp AP–PCR amplified product with reduced intensity in 5
(T2,T 3,T 4,T 5, and T11 of the Wilms tumour DNA samples as compared to
the corresponding normal kidney tissue DNA from same patient.
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regions
The cause for the multifold decreased intensity of 475bp AP-PCR
amplified locus in the tumour samples could be due to either
mutation (s) at the primer-binding site(s) and/or due to deletion of
this region in the genome of Wilms tumours.
Sequence Characterised Amplified Region (SCAR) analysis was
performed to investigate whether the loss of 475bp AP-PCR
amplified region is a result of allelic loss. Using SKCG-1- specific
primer as mentioned in RT-PCR section of materials and methods,
we amplified genomic sequence of SKCG-1 from Wilms tumours
and their corresponding uninvolved kidney tissue DNA. The
combination of two SCAR primers generated a single PCR
amplified fragment of expected size (300bp); however, the
intensity of this fragment was reduced to almost half in tumours
as compared to their corresponding uninvolved tissue samples
(Figure 2A). The tumour samples showing reduced intensity in
SCAR analysis were the same samples that revealed reduced
intensity in 475bp AP-PCR amplified fragment (samples T2,T 3,T 4,
T5 in Figures 1 and 2A). Thus, the result of SCAR analysis indicates
loss of one allele of SKCG-1 in the tumours. Matching normal
tissue samples were uninvolved surrounding tissue of tumours.
One of the normal (N5) tissues DNA consistently produced a
profile similar to the matching tumour in both AP-PCR (Figure 1,
lane 10) and SCAR amplification (Figure 2A, lane 9). This could be
explained by the presence of similar genetic changes in tumour as
well as in the surrounding pathologically normal tissue (N5).
Though these cells have undergone the genetic changes, however,
they have still not been morphologically changed. Thus, some of
the pathologically normal looking cells may not be genetically
normal.
We also performed Southern blot analysis with samples where
enough DNA was available for this study. Presence of a
hybridisation signal in uninvolved kidney tissue DNA and its
absence in the corresponding tumour DNA was observed
(Figure 2B). Thus, the result of Southern blot analysis confirmed
the loss of SKCG-1 genomic region in Wilms tumour tissue.
In order to identify mutations, if any, in the SKCG-1 allele that is
still present in the tumour, genomic sequence of SKCG-1 (from
base þ1t oþ1692) was amplified from DNA of tumour as well as
from matching normal tissue and sequenced. Comparison of
sequence from normal tissue DNA with corresponding tumour
tissue DNA did not reveal any mutation in the SKCG-1 allele in
tumours.
Determination of transcript size of SKCG-1 gene by
Northern
To determine the size of the SKCG-1 gene transcript, Northern
analysis was performed with total RNA isolated from HEK293 cells
derived from human embryonic kidney and using the PCR-
generated probe as described in material and methods. A single
band corresponding to the SKCG-1 transcripts of B2.1kb was
observed (Figure 3).
Isolation of full-length cDNA by RACE
The AP-PCR amplified product of 475bp with primer OPA14 using
DNA from uninvolved kidney tissue was gel eluted, reamplified,
cloned and sequenced as described in material and methods. The
final DNA sequence of 475bp AP-PCR fragment (Figure 4, from
þ1089 to þ1564) obtained from five different clones was
compared with the known gene/genomic sequence in the GenBank.
BLAST analysis revealed that there was a complete match (100%
sequence similarity) of 475bp sequences with Homosapiens
chromosome 11 working draft sequence segment (NT_033899.7)
and genomic clone (accession number AP003027) from human
chromosome 11q as well as with one of the human expressed
sequence tag (EST) (accession number AA935177). Interestingly,
this EST has been reported from the cDNA library made from
human kidney tumour tissue. By sequencing of this EST clone, we
obtained 1.37kb of SKCG-1 (Figure 4, from þ133 to þ1503).
Finally, 2.09kb full-length cDNA sequence of SKCG-1 was obtained
by performing 50 and 30 rapid amplification of cDNA ends (RACE)
using the 1.37kb sequence information. 50 RACE added 0.133kb
(Figure 4, from þ1t oþ133) whereas the remaining 0.587kb
sequence (Figure 4, from þ1503 to þ 2090) was obtained by 30
RACE. The size of the 2.09kb full-length transcript was very close
to that of 2.1kb as determined by northern. A comparison of the
full-length cDNA sequence obtained by RACE with the genomic
sequence revealed that this transcript is of single exon without any
intervening intron sequence. Full-length cDNA sequence of SKCG-1
N1 T1 N2 T2 N3 T3 N4 T4 N5 T5
SKCG1
(300 bp)
 
10 123456789
A
B
-actin
N        T N         T N           T
SKCG-1 SKCG-1 GAPDH
Bam HI digest Sma I digest  Sma I digest
Figure 2 Sequence characterised amplified region (SCAR) (A) and
Southern blot (B) analysis showing genomic loss of SKCG-1 in Wilms
tumours (T) and its presence in corresponding uninvolved normal (N)
kidney tissue. The primers used for SCAR amplification are mentioned in
Materials and Methods section. Restriction enzymes, BamH1 and Sma1
digested genomic DNA (10mgs) from Wilms tumours (T) and correspond-
ing uninvolved (N) tissue was separated by electrophoresis, transferred to
nylon membrane and hybridised with radioactive-labelled SKCG-1-or
GAPDH-specific probe as mentioned in materials and methods. Arrow
signs in figures indicate the hybridisation signal of SKCG-1 in uninvolved
normal tissue DNA and its loss in the tumour DNA sample. Control
hybridisation with GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
probe verified the equal amount of DNA loaded.
~2.1 kb
SKCG-1
GAPDH
5 g
10 g
20 g
Figure 3 Northern blot analysis of SKCG-1. Total RNA isolated from
immortalised embryonic kidney epithelial cells (HEK 293) was separated by
electrophoresis, transferred to nylon membrane and hybridised with
nonradioactive PCR generated-DIG-labelled SKCG-1 gene-specific probe.
Control hybridisation with GAPDH (Glyceraldehydes-3-phosphate dehy-
drogenase) probe verified the amount of RNA loaded.
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shas been submitted to the NCBI database and the assigned GenBank
accession number for SKCG-1 is AY662656.
Distribution of SKCG-1 gene expression in various human
tissues
To determine the distribution of SKCG-1 gene transcript in various
human tissues, PCR amplification with SKCG-1 gene-specific
primer was performed on a panel of cDNA from various human
tissues (Origene Inc). SKCG-1 gene-specific amplification product
of expected size (300bp) was abundantly present in brain, kidney,
liver, testis, salivary gland, foetal brain, foetal liver, whereas
relatively lower expression of this gene transcript was found in
heart, small intestine, muscle, stomach, placenta, and prostate
(Figure 5). No expression of this gene transcript was detected in
spleen, colon, lung, adrenal gland, pancreas, uterus, skin, PBL, and
bone marrow (Figure 5). An amplification product of higher size
(B360bp) in placenta and a lower size (B270bp) in pancreas was
observed (Figure 5).
Expression of SKCG-1 gene transcript in Wilms and breast
tumours, and their corresponding uninvolved tissue
We examined the expression pattern of SKCG-1 gene transcripts by
semi-quantitative RT–PCR analysis in Wilms (N¼4) and breast
(N¼7) tumours and their corresponding uninvolved tissues.
Expression of this gene was found to be either completely absent
or hardly detectable in Wilms (Figure 6A) and breast (Figure 6B)
tumours; however, its expression was readily detectable in their
corresponding uninvolved tissues. These Wilms tumour samples
Figure 4 Full-length cDNA sequence and deduced amino-acid sequence of SKCG-1. The full-length SKCG-1 cDNA encodes a predicted polypeptide of
124 amino acids. The polyadenylation signal is underlined. Sequence has been submitted to the NCBI database and the assigned GenBank accession number
for SKCG1 is AY662656.
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(T2,T 3,T 4, and T5, Figures 1 and 6A). An amplification product of
higher size (320bp) was observed in one of the breast tumour
sample (Figure 6B, lane 7).
Silencing of SKCG-1 by siRNA in HEK 293 cells
To determine the extent of gene silencing by siRNA, the total RNA
was isolated from HEK293 cells at 48-h post-transfection and
semiquantitative RT-PCR was performed. The SKCG-1 gene
transcript in siRNA-transfected cells was much lower as compared
to the controls, indicating thereby the silencing of the gene
(Figure 7A). To investigate whether the silencing of SKCG-1 gene
has any effect on the cell growth, we performed cell counts before
isolating the RNA. The cell counts data revealed a 40% increase in
the growth of human embryonic kidney cells as a result of SKCG-1
gene silencing compared with the growth of control cells with
constitutive expression of SKCG-1 (Figure 7B).
Chromosomal localisation of SKCG-1 by fluorescence in
situ hybridisation (FISH)
Initial experiment of FISH with human BAC clone containing
475bp region of SKCG-1 gene as a probe resulted in the specific
hybridisation signal on the long arm of a group C chromosome
that was believed to be chromosome 11 on the basis of size,
morphology, and banding pattern. A second experiment with a
biotin-labelled probe, which was specific for the centromere of
chromosome 11, was cohybridised with SKCG-1 BAC clone. This
experiment resulted in the specific labelling of the centromere in
red and long arm in green of chromosome 11. Measurement of 10
specifically labelled chromosome 11 demonstrated that SKCG-1
BAC clone is located at a position, which is 73% of the distance
from the centromere to the telomere of chromosome arm 11q, an
area that corresponds to band 11q23.2 (Figure 8). A total of 80
metaphase cells were analysed with 75 exhibiting specific
hybridisation signal.
Structural analysis and coding potential of SKCG-1 gene
Analysis of 2kb upstream genomic sequence of SKCG-1 revealed a
promoter region containing TATA box located at  13bp upstream
of transcription start site (underlined in Figure 4). Bioinformatic
analysis using software program (www.ebi.ac.uk/servicestmp)
revealed potential methylation sites (CpG lots) located between
 600 to  900bp in the promoter region of SKCG-1. This region
corresponds to nucleotide 106503–106803 of human genomic
clone, NCBI accession number AP003027. Sequence analysis of
SKCG-1
(300 bp)
SKCG-1
(300 bp)
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Figure 5 Distribution of SKCG-1 gene expression in various human
tissues. Expression of SKCG-1 gene among the various tissues analysed by
SKCG-1 gene-specific PCR using tissue-specific cDNA panel (OriGene
Technologies). Arrow indicates the expected size (300bp) PCR product of
SKCG-1 from tissue-specific cDNA.
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Figure 6 Semiquantitative RT–PCR analysis of SKCG-1 transcript in
human Wilms (A), and breast (B) tumours (T) and corresponding
uninvolved normal (N) kidney tissue. Amplification of b-actin or GAPDH
was used as control for similar amount of RNA taken for RT reaction.
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Figure 7 Effect of siRNA-mediated silencing of SKCG-1 transcripts on
the growth of human embryonic kidney epithelial cells. (A) SKCG-1 gene-
specific siRNA oligos was transfected into HEK293 cells. Cells treated in
parallel with transfection reagent without siRNA oligos served as control in
transfection experiment. After 48h of transfection, the total RNA was
isolated, RT was performed, and transcript level was detected by PCR using
SKCG-1 specific primers. Amplification of b-actin was used as control for
similar amount of RNA taken for RT reaction. (B) Histogram showing the
siRNA concentrations transfected and its effect on the growth of HEK 293
cells.
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s2.09kb full-length cDNA revealed two translation start sites (ATG
sequence) present at þ101 and þ1327bp (represented by bold
letters in Figure 4), and a polyadenylation signal sequence
(AATAAA) present at þ2062bp (represented by italics in
Figure 4). ORF analysis revealed that the cDNA sequence of this
gene has an open reading frame encoding a protein of 124 amino
acids in frame þ1 (Figure 4). Domain analysis using NCBI
conserve domain database revealed that this gene does not have
any conserved functional domain. The EMBL bioinformatic
harvester program Website has analysed the detail structure of
SKCG-1 peptide. SOSUI software system has detected two
transmembrane helices in the SKCG-1 peptide. The primary
transmembrane helices is represented by transmembrane region
(N-terminal, AAno.24)-SIYYLLLWVKTNLSVSAVCKLAW- (C-
terminal, AAno.46) and the secondary transmembrane helices is
represented by transmembrane region (N-terminal, AAno.86)-
VCKCFLCEALAWKHLNLIALYVC- (C-terminal, AAno.108) in
SKCG-1 peptide. On the basis of the presence of these two
transmembrane helices, the SKCG-1 has been predicted as a
transmembrane protein. The predicted probability value of its
localisation is 44.4% for extracellular including cell wall, 22.2% for
cytoplasmic, 11.1% for golgi, 11.1% for nuclear, and 11.1% for
endoplasmic reticulum. The detail structure of SKCG-1 peptide,
location of transmembrane region and its hydropathy profile as
well as helical wheel diagram is available at the EMBL bioinfor-
matic harvester website (http://harvester.embl.de/harvester/
Q51SC8).
No significant homology (over full-length cDNA of SKCG-1)o f
this gene with any known gene in NCBI GenBank database was
found. However, sequence similarity search using database of
Celera Genomics revealed that SKCG-1 had 89% similarity over a
229-nucleotide stretch and 85% similarity over a 62-nucleotide
stretch with a solute carrier family 14 (urea transporter) gene
(Celera accession number NP_009094) reported from human
kidney by Olives et al (1996) (Figure 9A). BLAST analysis revealed
that a portion (from þ497 to þ522) of SKCG-1 gene has
significant homology (96% identity) with several cDNA clones, for
example, NCBI accession numbers BU542594, BU632939,
BU543849, BQ013859, BM993263, BF002848), indicating thereby
Figure 8 Chromosome localisation of SKCG-1 ascertained by fluores-
cence in situ hybridisation analysis. Left panel: Representative metaphase is
shown exhibiting specific hybridisation signal (green fluorescent) on the
long arm of chromosome 11. A centromeric probe specific to the
chromosome 11 was simultaneously hybridised (Red fluorescent). No
signal was detected on any other chromosome using these probes. Right
panel: Two ideograms illustrating the chromosomal position of SKCG-1 at
11q23.2.
Figure 9 Sequence alignment at cDNA level of SKCG-1 with a solute carrier family 14 (urea transporter) gene (A), and SOS2-like protein kinase
mRNA (B).
SKCG-1: a new candidate growth regulatory gene
KP Singh and D Roy
1530
British Journal of Cancer (2006) 94(10), 1524–1532 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sthat this region represents a conserved sequence across these
genes. Another potentially important region found was a stretch of
27 nucleotides starting from þ1( 5 0-end) that revealed 100%
sequence identity with SOS2-like Protein Kinase mRNA, accession
number AF 525402.1 (Figure 9B).
DISCUSSION
The most important finding of this study is the identification of an
uncharacterised growth regulatory gene located at q23.2 region of
chromosome 11. We observed genomic loss of this gene in 38%
of the human Wilms tumour samples analysed. Several genes
of pathogenic significance, for examples, RCK, PLZP, LPC, RCK,
in haematopoietic neoplasm have been mapped to 11q23
(Stilgenbauer et al, 1996). However, no gene/gene mutations have
been identified at 11q 23.2, and hence this is the first report of
identification of a gene at this chromosomal region from Wilms
tumour.
Our data indicate that the expression of SKCG-1 gene at
transcript level is either completely absent or undetectable in
Wilms and breast tumour samples. Interestingly, those Wilms
tumour samples that had genomic loss of SKCG-1 also had reduced
or loss of SKCG-1 transcript (Figures 1 and 6). This coincidence of
loss at DNA level, and loss of gene expression at transcript level
within a tumour indicates that presumably reduced/loss of this
gene expression is a consequence of either complete loss
(homozygous deletion) as observed in Southern blot analysis, or
loss of one allele and/or silencing of remaining one allele by
mutations/promoter methylation. Sequence analysis of the allele
that is still present in tumours did not reveal any mutation. Thus
more than 50% reduction in the expression in some samples could
be due to loss of one allele by deletion and silencing of the
remaining allele possibly by methylation of SKCG-1 promoter
region. Presence of potential CpG lots in the SKCG-1 promoter
region further supports the probability of SKCG-1 promoter region
methylation as a causal factor for the silencing of expression of the
allele that is still present in tumours. However, further study is
needed to identify the exact cause for the loss of expression of
SKCG-1 allele that is still present in tumour.
We did not find any association of the observed genetic
alteration with either specific histopathology, grade and stage of
tumour or age as well as race of the patients in the samples used in
this study. However, it seems that this genetic alteration is more
frequent in female genetic background than in male as four out of
five samples showing genetic alteration and loss of gene expression
were from female patients. This gender-associated genetic altera-
tion in SKCG-1 remains to be validated by more number of
samples.
Though we have not confirmed tumour suppressor activity of
SKCG-1, however, the loss of expression of SKCG-1 in highly
proliferative human Wilms and breast tumours suggest that it is a
potential growth regulatory gene. A 40% increase in the cell growth
as a result of siRNA-mediated silencing of this gene in human
embryonic kidney epithelial cells further strengthens the fact that
SKCG-1 controls the growth/proliferation of human kidney
epithelial cells. The expression of SKCG-1 in various tissue
including kidney and its loss in Wilms and breast tumours
indicates that this gene is not kidney specific and it may have a role
in other tissue too. Whether the SKCG-1 has similar growth
regulatory function as observed in kidney tissue, and its loss of
expression in their corresponding tumour tissue, remains to be
investigated. The observed RT–PCR product of higher than the
expected size in placenta and in one of the breast tissue samples,
and lower than expected size in pancreas indicates that the spliced
forms of SKCG-1 also exits.
The most striking feature of the SKCG-1 full-length cDNA
sequence is the presence of very small open reading frames. The
biggest open reading frame found in this gene was of 124 amino
acids in frame þ1. The alternative use of CTG or ACG as the
initiation codon for translation (Kozak, 1996) does not signifi-
cantly lengthen any of the open reading frames. On the basis of the
presence of polyadenylated RNA molecule, several genes have been
ruled out being as pseudogenes (Bussemakers et al, 1999). As the
SKCG-1 is expressed as polyadenylated RNA molecule with an
ORF, and has function in controlling the cell growth as evident by
siRNA silencing, the possibility of SKCG-1 gene as a pseudogene
can be ruled out.
Thus, in the perspective of the function of this gene, there are
two logical explanations: (i) either it encodes for a very small
functional protein or, (ii) it acts as a riboregulator. The evidence in
favour of the first explanation that it encodes for a small functional
protein is that it has DNA sequence similarity with urea
transporter gene and also with protein kinase. The prediction of
SKCG-1 as a transmembrane protein based on the presence of two
transmembrane helices in its peptide further strengthens the
possibility of SKCG-1 as urea transporter gene in the membrane.
However, further study is needed to ascertain whether it encodes
any protein and its function as a transporter located in the
membrane.
The other possibility of this gene being a riboregulator cannot
be ruled out as well. In the last few years an emerging group of
mRNA-like noncoding RNAs have been discovered whose function
and mechanisms of action remain poorly understood (Erdmann
et al, 2001). This group of RNA lacks a protein coding capacity,
and most probably they exert their action mainly or exclusively at
the RNA level. These RNA molecules that function as genetic
regulators are also known as ‘RNA riboregulator’. There are
growing evidences which suggest that these riboregulators have
important biological functions in development, differentiation,
DNA damage, heat-shock responses, and tumorigenesis (Crespi
et al, 1994; Velleca et al, 1994; Takeda et al, 1998). Several genes,
for example, H19, His-1, Bic, that code for functional noncoding
mRNAs have been found to play role in tumorigenesis (Askew and
Xu, 1999). On the basis of our first report of identification and
characterisation of SKCG-1 gene, we propose that SKCG-1 belongs
to a distinct class of gene with potential function in kidney cell
biology and in kidney tumorigenesis. In this report with several
experiments we have provided the evidences for the role of SKCG-1
in growth control of malignant and normal kidney epithelial cells
as well as its loss of expression in Wilms and breast tumours. Thus,
our results support the potential value of SKCG-1 as new target for
future clinical therapies to restore the normal cellular function of
kidney and breast tissue.
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